Heart Failure NYHA Class III: Clinical Trials

4 trials for Heart Failure NYHA Class III, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 not yet recruiting, 1 recruiting, 1 unknown, 1 withdrawn. 4 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Not yet recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1
Phase 12Not yet recruiting 1, Unknown 1
Phase 31Recruiting 1

Follow Heart Failure NYHA Class III: new trials by email Literature Review of Heart Failure NYHA Class III trials Research Report on Heart Failure NYHA Class III

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Narrative Intervention for Chronic Illness- Heart Failure Trial (NICI-HF)
Narrative Intervention for Chronic Illness-Heart Failure, Attention Control - Heart Failure, Heart Failure NYHA Class III
Phase 1 / Phase 2Not yet recruitingUniversity of Colorado, Denver3002025-09-012024-11-13
Optimizing HFrEF Patients Using BaroStim and CardioMems
BaroStim - Heart Failure NYHA Class III
Phase 2 / Phase 3RecruitingNorthwell Health152025-01-172026-02-10
Biomarker Study: Heart Failure Patients at Risk
Angiotensin 1-7, Saline solution - Heart Failure NYHA Class II, Heart Failure NYHA Class III
Phase 1 / Phase 2UnknownUniversity of Arizona402022-04-012022-04-20
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid - Heart Failure NYHA Class I, Heart Failure NYHA Class II
Phase 2WithdrawnVanderbilt University Medical Center2017-09-012018-01-11

Narrower conditions

Heart Failure (2)

Broader conditions

Cardiovascular Diseases (2)  ·  Heart Diseases (2)

Interventions

BID protein, human (1)  ·  Enalapril (1)  ·  Saline Solution (1)  ·  Valsartan (1)  ·  angiotensin I (1-7) (1)  ·  icatibant (1)  ·  sacubitril and valsartan sodium hydrate drug combination (1)

Sponsors

Northwell Health (1)  ·  University of Arizona (1)  ·  University of Colorado, Denver (1)  ·  Vanderbilt University Medical Center (1)

Countries

United States (3)

Top investigators

John Kassotis, MD (1)  ·  Lee Ryan, Ph.D. (1)